Abstract |
We studied the efficacy and pharmacokinetics of imatinib mesylate (IM) and bcr-abl expression in a Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) patient, a rare disease with a poor prognosis. Although sufficient IM trough concentrations were maintained, bcr-abl transcripts revealed only one-log reduction with IM monotherapy, suggesting a resistance against IM, and this patient required additional chemotherapy. Despite the resistance against IM at induction therapy, the patient has been in complete molecular response for more than 6 months with IM maintenance monotherapy. Our experience suggests that IM might have a positive role in consolidation and/or maintenance therapy in remission Ph + AML patients.
|
Authors | Toshinori Kondo, Taizo Tasaka, Fuminori Sano, Kimiko Matsuda, Yasutaka Kubo, Yoshiko Matsuhashi, Hidekazu Nakanishi, Yoshito Sadahira, Hideho Wada, Takashi Sugihara, Kaoru Tohyama |
Journal | Leukemia research
(Leuk Res)
Vol. 33
Issue 9
Pg. e137-8
(Sep 2009)
ISSN: 1873-5835 [Electronic] England |
PMID | 19371951
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Piperazines
- Pyrimidines
- Imatinib Mesylate
|
Topics |
- Aged
- Antineoplastic Agents
(blood, pharmacokinetics, therapeutic use)
- Benzamides
- Chromatography, High Pressure Liquid
- Genes, abl
- Humans
- Imatinib Mesylate
- Leukemia, Myeloid, Acute
(drug therapy, genetics)
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
(drug therapy, genetics)
- Male
- Mass Spectrometry
- Piperazines
(blood, pharmacokinetics, therapeutic use)
- Polymerase Chain Reaction
- Pyrimidines
(blood, pharmacokinetics, therapeutic use)
|